References
- Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol 2020;72:250-261.
- Liu S, Yao X, Zhang D, Sheng J, Wen X, Wang Q, et al. Analysis of transcription factor-related regulatory networks based on bioinformatics analysis and validation in hepatocellular carcinoma. Biomed Res Int 2018;2018:1431396.
- Shen S, Kong J, Qiu Y, Yang X, Wang W, Yan L. Identification of core genes and outcomes in hepatocellular carcinoma by bioinformatics analysis. J Cell Biochem 2019;120:10069-10081.
- Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-1255.
- Zhang L, Maddox AS. Anillin. Curr Biol 2010;20:R135-R136.
- Chuang HY, Ou YH. Abstract 4068: overexpression of anillin in colorectal cancer promotes the cell proliferation, cell mobility and cell invasion. Cancer Res 2014;74(19 Suppl):4068.
- Zhang LH, Wang D, Li Z, Wang G, Chen DB, Cheng Q, et al. Overexpression of anillin is related to poor prognosis in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2021;20:337-344.
- Xu Z, Zhang Q, Luh F, Jin B, Liu X. Overexpression of the ASPM gene is associated with aggressiveness and poor outcome in bladder cancer. Oncol Lett 2019;17:1865-1876.
- Xie JJ, Zhuo YJ, Zheng Y, Mo RJ, Liu ZZ, Li BW, et al. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer. Int Urol Nephrol 2017;49:817-823.
- Lin SY, Pan HW, Liu SH, Jeng YM, Hu FC, Peng SY, et al. ASPM is a novel marker for vascular invasion, early recurrence, and poor prognosis of hepatocellular carcinoma. Clin Cancer Res 2008;14:4814-4820.
- Qiu J, Zhang S, Wang P, Wang H, Sha B, Peng H, et al. BUB1B promotes hepatocellular carcinoma progression via activation of the mTORC1 signaling pathway. Cancer Med 2020;9:8159-8172.
- Chai N, Xie HH, Yin JP, Sa KD, Guo Y, Wang M, et al. FOXM1 promotes proliferation in human hepatocellular carcinoma cells by transcriptional activation of CCNB1. Biochem Biophys Res Commun 2018;500:924-929.
- Zhao J, Han SX, Ma JL, Ying X, Liu P, Li J, et al. The role of CDK1 in apoptin-induced apoptosis in hepatocellular carcinoma cells. Oncol Rep 2013;30:253-259.
- Zhou J, Han S, Qian W, Gu Y, Li X, Yang K. Metformin induces miR378 to downregulate the CDK1, leading to suppression of cell proliferation in hepatocellular carcinoma. Onco Targets Ther 2018;11:4451-4459.
- Ito Y, Takeda T, Sakon M, Monden M, Tsujimoto M, Matsuura N. Expression and prognostic role of cyclin-dependent kinase 1 (cdc2) in hepatocellular carcinoma. Oncology 2000;59:68-74.
- Fan C, Chen L, Huang Q, Shen T, Welsh EA, Teer JK, et al. Overexpression of major CDKN3 transcripts is associated with poor survival in lung adenocarcinoma. Br J Cancer 2015;113:1735-1743.
- Dai W, Miao H, Fang S, Fang T, Chen N, Li M. CDKN3 expression is negatively associated with pathological tumor stage and CDKN3 inhibition promotes cell survival in hepatocellular carcinoma. Mol Med Rep 2016;14:1509-1514.
- Chen J, Xia H, Zhang X, Karthik S, Pratap SV, Ooi LL, et al. ECT2 regulates the Rho/ERK signalling axis to promote early recurrence in human hepatocellular carcinoma. J Hepatol 2015;62:1287-1295.
- Jin Y, Yu Y, Shao Q, Ma Y, Zhang R, Yao H, et al. Up-regulation of ECT2 is associated with poor prognosis in gastric cancer patients. Int J Clin Exp Pathol 2014;7:8724-8731.
- He Z, Mei L, Connell M, Maxwell CA. Hyaluronan mediated motility receptor (HMMR) encodes an evolutionarily conserved homeostasis, mitosis, and meiosis regulator rather than a hyaluronan receptor. Cells 2020;9:819.
- Lin S, Zhou S, Jiang S, Liu X, Wang Y, Zheng X, et al. NEK2 regulates stem-like properties and predicts poor prognosis in hepatocellular carcinoma. Oncol Rep 2016;36:853-862.
- Fu L, Liu S, Wang H, Ma Y, Li L, He X, et al. Low expression of NEK2 is associated with hepatocellular carcinoma progression and poor prognosis. Cancer Biomark 2017;20:101-106.
- Yang QX, Zhong S, He L, Jia XJ, Tang H, Cheng ST, et al. PBK overexpression promotes metastasis of hepatocellular carcinoma via activating ETV4-uPAR signaling pathway. Cancer Lett 2019;452:90-102.
- Wang Y, Shi F, Xing GH, Xie P, Zhao N, Yin YF, et al. Protein regulator of cytokinesis PRC1 confers chemoresistance and predicts an unfavorable postoperative survival of hepatocellular carcinoma patients. J Cancer 2017;8:801-808.
- Imaoka H, Toiyama Y, Saigusa S, Kawamura M, Kawamoto A, Okugawa Y, et al. RacGAP1 expression, increasing tumor malignant potential, as a predictive biomarker for lymph node metastasis and poor prognosis in colorectal cancer. Carcinogenesis 2015;36:346-354.
- Wang SM, Ooi LL, Hui KM. Upregulation of Rac GTPase-activating protein 1 is significantly associated with the early recurrence of human hepatocellular carcinoma. Clin Cancer Res 2011;17:6040-6051.
- Nana AW, Wu SY, Yang YS, Chin YT, Cheng TM, Ho Y, et al. Nano-diamino-tetrac (NDAT) enhances resveratrol-induced antiproliferation by action on the RRM2 pathway in colorectal cancers. Horm Cancer 2018;9:349-360.
- Lee B, Ha SY, Song DH, Lee HW, Cho SY, Park CK. High expression of ribonucleotide reductase subunit M2 correlates with poor prognosis of hepatocellular carcinoma. Gut Liver 2014;8:662-668.
- Zhao Q, Li H, Zhu L, Hu S, Xi X, Liu Y, et al. Bioinformatics analysis shows that TOP2A functions as a key candidate gene in the progression of cervical cancer. Biomed Rep 2020;13:21.
- Wong N, Yeo W, Wong WL, Wong NL, Chan KY, Mo FK, et al. TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. Int J Cancer 2009;124:644-652.